CD79A

Across TCGA pan-cancer cohorts, CD79A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD79A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CD79A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD79A expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where CD79A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.216	0.654	.032	18	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
SKCM	DFS	Median	All	1.000	0.212	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD79A–BLCA (OS)

Open the BLCA breakdown →